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Purpose: The objective of this study was to report the experience acquired at the Seoul National University Hospital with Hol-
mium Laser Enucleation of Prostate (HoLEP), combined with mechanical morcellation for symptomatic benign prostatic hy-
perplasia (BPH).
Methods: A retrospective review was performed on the clinical data of 309 consecutive patients who underwent HoLEP at our 
institution between July 2008 and June 2010. All patients were evaluated preoperatively for prostate volume by transrectal ultra-
sound, maxi  mum urinary flow rate (Qmax), International Prostate Symptoms Score (IPSS) and quality of life (QoL) score. Peri- 
and postoperative parameters were evaluated and patients were followed-up at 1-, 3-, 6-, and 12- months with the aforementioned 
investigations.
Results: The patients’ mean age was 68.3 (±6.5) years and mean prostate volume was 55.6 (±23.6) mL. Mean enucleation time 
was 56.2 (±25.1) minutes, mean morcellation time was 11.3 (±9.5) minutes, and the mean resected weight of the prostate was 
20.8 (±16.9) g. The mean catheter indwelling period was 1.9 (±1.7) days and mean hospital stay was 2.9 (±1.5) days. Signifi-
cant improvement was noted in Qmax, IPSS, and QoL at the 1-year follow-up compared with baseline (P<0.01). At 1 month 
17.2% of patients complained of irritative urinary symptoms, which were typically self-limiting within 3 months. Transient stress 
incontinence was reported in 15.2% of patients. No patient experienced persistent obstructive symptoms that required reopera-
tion.
Conclusions: Our study showed that HoLEP is a safe and effective therapeutic modality for BPH.
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INTRODUCTION
Lower urinary tract symptoms (LUTS) due to benign prostatic 
hyperplasia (BPH) are major cause of discomfort among elderly 
men [1]. Transurethral resection of prostate (TURP) has been 
accepted as the gold standard for the surgical management of 
symptomatic BPH [2]. Recently, however, relatively less invasive 
treatment modalities have been introduced, resulting in lower 
morbidity and excellent voiding symptom improvement [3].
  In 1995, the first description of laser prostatectomy using a 
Holmium laser was published by Gilling [4]. Ever since the in-
troduction of Holmium laser enucleation of prostate (HoLEP), 
it has become accepted as a treatment modality with excellent 
outcomes. Compared with conventional treatment modalities, 
such as TURP and open prostatectomy, HoLEP shows similar 
postoperative outcomes associated with lower morbidities [5,6].
In 2008, the HoLEP procedure became popularized in the Re-
public of Korea for the treatment of BPH. Despite a steep learn-
ing curve, this technique has been acquired by many Korean 
urologists. Although results over a 3-year follow-up period have 
been reported by foreign groups, mid-term postoperative fol-
low-up results have not been reported in Korea [5]. Two years 
after the introduction of HoLEP, we herein present our inter-
mediate-term follow-up results.
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MATERIALS AND METHODS
A retrospective study was conducted in 309 patients complain-
ing of LUTS who underwent HoLEP combined with morcella-
tion at our institute by two surgeons (SJO, JSP) between July 
2008 and June 2010. All patients presented with LUTS due to 
BPH with or without bladder overactivity. Patient demograph-
ics, including medical history and pre- and postoperative status 
were reviewed. Preoperative parameters such as; physical ex-
amination including digital rectal examination, urinalysis and 
urine culture, serum prostate-specific antigen (PSA), Interna-
tional Prostate Symptom Score (IPSS) questionnaire with quali-
ty of life (QoL) and uroflowmetry (UFM) with post void resid-
ual (PVR) measurement by ultrasound were investigated. Pros-
tate volume and transitional zone volume were measured by 
using transrectal ultrasound (TRUS). When prostate cancer 
was clinically suspected, preoperative prostate biopsy was per-
formed. Postoperatively, IPSS, UFM and PVR were investigated 
during follow-up at 1, 3, 6, and 12 months. Serum PSA and 
TRUS measurements were performed at 6 months. The postop-
erative biopsy result was recorded if malignant neoplasm was 
present. Some patients underwent cystoscopic examination for 
urinary tract complications.
  Operative procedures were similar to those described previ-
ously [7]. Briefly a 26Fr resectoscope (Karl Storz GmbH & Co., 
Tuttlingen, Germany) was used for enucleation of the prostate. 
A 550 μm end-firing laser fiber (SlimLine, Lumenis Ltd, 
Yokneam, Israel) was engaged with an 80 W holmium neo-
dymium: yttrium-aluminum-garnet laser (VersaPulse Power-
Suite, Lumenis Ltd). Energy power was usually set at 2 J and 50 
Hz, and for hemostasis at 2 J and 40 Hz. Continuous irrigation 
was applied with normal saline during enucleation and morcel-
lation. Tissue morcellation was performed with a VersaCut 
morcellator (Lumenis Ltd) through a 0 degree rectangular 
nephroscope (Karl Storz GmbH & Co.). During the transure-
thral procedure the outer sheath was always in the urethra, be-
cause the resectoscope and nephroscope were exchangeable in 
the outer sheath. At completion of the morcellation, a 22Fr 
3-way urethral catheter was inserted for continuous bladder ir-
rigation with normal saline. Most patients were discharged after 
Foley catheter removal the following day.
  Operative documents captured enucleation time, morcella-
tion time, retrieved tissue weight, pathologic findings, catheter 
time, hospital stay and operation-related complications. Com-
plications included perioperative events (capsular perforation, 
mucosal injury, transfusion, clot retention, recatherterization), 
postoperative sustaining voiding symptoms (incontinence, irri-
tative symptoms, urinary tract infection [UTI]) and postopera-
tive morbid finding (urethral stricture, bladder neck contrac-
ture). Data were statistically analyzed by using the Student’s t-test 
or analysis of variance, and are presented as ranges and means± 
standard deviation of the mean.
  This study was approved by the Institutional Review Board 
of Seoul National University Hospital.
RESULTS
The baseline characteristics of the patients are summarized in 
Table 1. Mean patients age was 68.3 years. Most patients had 
previously received an alpha blocker. One third of the patients 
(116, 34.5%) had a prostate larger than 60 mL. Mean maxi-
mum urinary flow rate (Qmax) and PVR were 10.3 mL/sec 
and 72.2 mL, respectively. Mean follow-up duration was 12 
Table 1. Patient demographics 
Parameters Value
No. of patients 309
Age (yr) 68.3 (51-88)
Symptom duration (mo) 27.1 (1-360)
BMI (kg/m
2) 24.1 (13.8-31.8)
Preoperative medical history
Diabetes melitus 51 (16.5)
Neurologic disease 35 (7.4)
Cardiovascular disease 25 (7.4)
Preoperative medications
Alpha-blocker  214 (69.3)
5a-reductase inhibitor 81 (26.2)
Anticholinergics 27 (8.7)
Evaluation data
Serum PSA (ng/mL) 3.5 (0.3-36.7)
Prostate volume (mL) 55.6 (11.9-162)
Transitional zone volume (mL) 29.5 (4-107)
Qmax (mL/sec) 10.3 (0.8-25)
IPSS 19.1 (3-35)
QoL 4.1 (1-6)
Values are presented as mean (range) or number (%).
BMI, body mass index; PSA, prostate-specific antigen; Qmax, maxi-
mum urinary flow rate; IPSS, international prostate symptom score; 
QoL, quality of life score.www.einj.org    31
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months (range, 6 to 28 months).
  Perioperative data are presented in Table 2. Seventeen (5%) 
patients who had bladder stones underwent lithotripsy by hol-
mium laser before enucleation of an adenoma. The mean enu-
cleation and morcellation efficiency were 0.37 g/min and 2.06 
g/min, respectively. The difference in operative efficiency ac-
cording to prostate size was statistically available for the param-
eters of enucleation efficiency and morcellation efficiency (data 
not shown). Only one patient underwent pure laser-assisted in-
cision of the bladder neck. 
  Table 3 shows parameters related to complications. Intraop-
erative complications included bladder injury (9.1%), capsular 
perforation (5.8%), additional transurethral resection (TUR) 
(16.5%), incomplete morcellation (6.5%) and sustained bleed-
ing during enucleation (25.6%). Mean catheter duration and 
hospital stay were 1.9 days and 2.9 days, respectively. Thus, 
most patients were discharged without a Foley catheter within 
3 days of admission. Five patients required subsequent coagula-
tion for bleeding control under anesthesia and two patients re-
quired only cystoscopic clot evacuation with local anesthesia. 
In this series, six patients required postoperative transfusion 
due to postoperative hemoglobin decrease. Thirty-one patients 
(9.1%) were recatheterized on the day of Foley removal or sev-
eral days later due to urinary retention. After recatheterization, 
removal of the Foley catheter was determined by clinical deci-
sion, taking into account patient age, general condition, comor-
bidity and operative findings. Extremely long catheter duration 
was related with patient’s comorbidities.
  During the follow-up, major complaints consisted of persis-
tent irritative symptoms (17.2%), UTI including epididymitis 
(2.6%), urinary incontinence (15.2%), and urethral stricture 
confirmed by urethroscopy (3.2%). These complications tended 
to improve within a few months. 
Table 2. Perioperative findings and operative efficiency
Parameters   Mean (range)
Enucleation time (min) 56.2 (10-180)
Morcellation time (min) 11.3 (1-90)
Used energy (KJ) 101.6 (11.3-233.6)
Resected weight (g) 20.8 (0.2-84.3)
Enucleation efficiency (g/min) 0.37 (0.01-1.47)
Morcellation efficiency (g/min) 2.06 (0.1-7.7)
Catheter duration (day) 1.9 (0-16)
Hospital stay (day) 2.9 (1-18)
Table 3. Perioperative complications
Types of complication No. (%)
Intraoperative
Adjuvant TURP 51 (16.5)
Incomplete morcellation 20 (6.5)
Bladder injury 28 (9.1)
Capsular perforation 18 (5.8)
Bleeding 79 (25.6)
False way of urethra 4 (1.3)
Immediate postoperative
Cystoscopic clot evacuation 2 (0.6)
Recatheterization 31 (10.0)
Reoperation for bleeding control 5 (1.6)
Transfusion 6 (1.9)
Urinary incontinence 38 (12.3)
Urgency 18 (5.8)
Postoperative 1 month (n= 309)
Urinary incontinence 47 (15.2)
Urgency 53 (17.2)
UTI 8 (2.6)
Dysuria 8 (2.6)
Urethral stricture 5 (1.6)
Postoperative 3 months (n=307)
Urinary incontinence 28 (9.1)
Urgency 31 (10.1)
UTI 2 (0.7)
Dysuria 3 (1.0)
Urethral stricture 5 (2.33)
Postoperative 6 months (n=168)
Urinary incontinence 12 (7.1)
Urgency 12 (7.1)
UTI 1 (0.6)
Dysuria 1 (0.6)
Urethral stricture 3 (1.8)
Postoperatively 12 months (n=106)
Urinary incontinence 5 (4.7)
Urgency 6 (5.7)
UTI 1 (0.9)
Dysuria 2 (1.9)
Urethral stricture 1 (0.9)
Postoperative medication
Anticholinergics 63 (20.4)
Alpha-blocker 6 (1.9)
Desmopressin 3 (1.0)
Malignancies postoperative pathology reported 17 (5.5)
TURP, transurethral resection of prostate; UTI, urinary tract infection.32    www.einj.org
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  Voiding parameters became favorable as follow-up contin-
ued (Table 4). Qmax and PVR were dramatically improved im-
mediately after the operation. At the 1-year follow-up, Qmax, 
IPSS, and QoL showed significant improvement compared with 
baseline (P<0.01). Within the prostate symptom score, howev-
er, the storage symptom score showed gradual improvement. 
Serum PSA decreased with statistical significance (P<0.01). 
Postoperative urinary incontinence appeared in 47 (15.2%) pa-
tients (urge 38, stress 29). Urinary incontinence appeared with-
in 1 month in most patients and persisted for about 2 months. 
Stress urinary incontinence was associated with prostate size 
(divided with cut off value 50 mL, P=0.046), intraoperative 
capsular perforation (P=0.045) and bladder mucosal injury 
(P=0.009), but was not correlated with preoperative presence 
of detrusor overactivity (P=0.204) and preoperative inconti-
nence (P=0.623).
  Indolent malignancies were detected in 17 patients, of whom 
1 patient experienced invasive transitional cell carcinoma (TCC) 
and the remainder presented with prostate adenocarcinoma. At 
the time of finalizing this article for publication, there had been 
no reoperations for recurrence of BPH.
DISCUSSION
As reported in the literature, HoLEP is assumed to provide em-
inent physical properties terms of BPH surgery and morbidity 
[3]. HoLEP has proven to be a good alternative to TURP and 
open prostatectomy with excellent hemostasis [5,6]. In 2008, 
HoLEP was introduced in Korea owing to its efficiency and 
safety. However, several challenges exist. A steep learning curve 
is the main hurdle to overcome for urologists, particularly in 
the initial phase of experience. According to several articles, the 
steep learning curve can be surmounted by performing consec-
utive HoLEP procedures [8-10]. After the initial experience, 
postoperative results should be analyzed once a consistent tech-
nique is applied. As such, we began to analyze intermediate-
term results 2 years after the introduction of HoLEP in Korea.
  Of the operative parameters, operative time and efficiency 
(including enucleation and morcellation) were comparable with 
previously reported outcomes [11,12]. In our previous series, 
after overcoming the learning curve, the efficiency of HoLEP 
became stable and the general operative parameters were con-
sistent [10]. Voiding parameters, such as Qmax and IPSS, which 
are indicative of voiding symptom relief, dropped immediately 
after the operation and this trend continued in the follow-up 
period. Regarding the storage symptom score sum, the range of 
reduction was not as wide as for the voiding symptom scores 
sum and Qmax in the first months. It was associated with rela-
tively high rates of irritative symptoms and incontinence during 
the initial follow-up period. A previous report on the mid-term 
outcomes of HoLEP confirmed its sustainability [5]. In the 
present report, there was no need for additional adenoma re-
section during the follow-up period. This observation showed 
the long-term durability of the operative outcomes.
  Regarding perioperative events, incomplete enucleation, ad-
ditional TUR and incomplete morcellation appeared in the ini-
tial and late series [10]. In cases of incomplete enucleation, we 
applied additional TUR to complete the prostate resection and 
to make the prostatic urethra surface smooth. If mechanical 
morcellation was imperfect, the remnant tissue was extracted 
Table 4. Voiding parameters as efficacy profile
Preoperative
(n=309)
Preoperative
 b)
(n=106)
1 mo
(n=302)
3 mo
(n=217)
6 mo
(n=167)
12 mo
(n=106)
Qmax (mL/sec) 10.3±4.6 10.6±4.1 18.7
 a)±9.8 19.8
 a)±11.1 19.5
 a)±8.5 19.5
 a)±9.5
PVR (mL) 72.2±100 93.1±118.1 22.9
 a)±32.8 22.9
 a)±42.4 21.1
 a)±39.7 18.9
 a)±38.4
IPSS 19.1±7.5 19.3±7.2 10.7
 a)±7.9 8.1
 a)±6.6 7.9
 a)±6.4 7.7
 a)±6.0
Voiding symptom 11.5±5.2 11.7±4.7 4.7
 a)±4.8 3.3
 a)±4.5 3.7
 a)±4.5 3.8
 a)±4.4
Storage symptom 7.7±3.5 7.9±3.6 6.2±4.1 4.8
 a)±3.1 4.2
 a)±2.9 3.9
 a)±2.7
QoL 4.1±1.1 4.2±1.2 2.8
 a)±1.7 2.1
 a)±1.5 1.7
 a)±1.5 1.8
 a)±1.4
Serum PSA (ng/mL) 3.5±4.1 3.5±4.7 1.0
 a)±0.8 1.0
 a)±0.7 1.1
 a)±0.7
Prostate vol (mL) 55.6±23.6 52.7±21.3 24.1
 a)±7.4
Qmax, maxi  mum urinary flow rate; PVR, post void residual; IPSS, international prostate symptom score; QoL, quality of life score; PSA, prostate-
specific antigen.
a)P<0.01 compared with preoperative parameters. 
b)Parameters of the patients whose 12 months follow-up was completed.www.einj.org    33
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by use fo cystoscopic foreign body forceps. The reason for this 
observation after surmounting the learning curve can be as-
sumed to be fibrotic tissue that was too firm to be easily en-
gaged by the laser fiber and morcellator blades [11]. Bladder in-
jury and capsular perforation could still be seen late in the se-
ries. This can be explained by the tendency of surgeons to per-
form rapid and complete operations; therefore, the risks of per-
foration did not decrease [10]. However, most complications 
had a tendency to decrease as experience was accumulated. In 
our series, there was only one case of full-thickness ureteral ori-
fice injury, whereas most cases were due to shallow mucosal in-
jury. Most cases of bladder injury were managed just like rou-
tine cases or in some were caused by prolonged indwelling of 
the urinary catheter. Capsular perforations were addressed by 
coagulation by TUR. The transfusion rate was 1.6%. Most cases 
were in the early series and the transfusion rate was comparable 
to that described in other reports [13]. 
  Irritative symptoms were the major complaints in the initial 
follow-up period. These symptoms were assumed to originate 
from capsular irritation by laser energy [14]. However, these 
were generally self-limiting within 3 months. Vavassori et al. 
[11] reported that the 28% of patients who complained of irri-
tative voiding symptom at the first follow-up month soon de-
creased to 10% within 3 months. These patients probably had 
inflammatory circumstances that may be related to tissue reac-
tivation in the prostate surgical plane [15]. In most patients the 
symptom grade was generally mild.
  In this series, the incidence of early urinary incontinence, in-
cluding urgency and stress, was relatively high (15.2%), but 
lower than in other series [14]. The incidence was reduced to 
9.1% at 3 months and to 7.1% at 6 months. Most patients im-
proved during the initial 6 months postoperatively, and the 
mean symptom duration was 2 months. Early urinary inconti-
nence might have originated from transient urethral dilatation 
of the prostate apex structure, resulting in temporal external 
sphincter damage [9]. To avoid this complication, Fong et al. 
[16] advocated prudence so as not to incise the sphincter base 
in the anterior area of the prostate. We analyzed the relationship 
between urinary incontinence and preoperative parameters. 
Comorbidities including diabetes mellitus, neurologic disease, 
and detusor overactivity on urodynamic study were not statisti-
cally related to incontinence. 
  Several studies indicated a lower incidence of urethral stric-
ture following HoLEP than after TURP and open prostatecto-
my [17,18]. In our series, the risk of urethral stricture was simi-
lar to TURP and open prostatectomy. Most strictures were 
found on the meatus or the bulbous urethra, which were gener-
ally dilated in the outpatient clinic. Only one patient experi-
enced recurrent urethral strictures and underwent repeated en-
doscopic urethrotomy. Urethral strictures, in this series, did not 
show any correlation with preoperative stricture or prostate 
size, whereas other researchers reported an association with the 
learning curve [13]. We found bladder neck contracture in two 
patients, first detected between 3 and 6 months of follow-up. 
This relatively low rate of stricture was due to gentle handling of 
the scope, preoperative calibration in some cases and lubrica-
tion during the procedure [6]. 
  The prostate size measured at 6 months revealed a mean de-
crease of 27.8 mL, comparable to the mean enucleation weight 
(20.8 g) gauged immediately after the operation. Although not 
all patients underwent measurement of prostate size at 6 mo-
nths, these data confirmed anatomical reduction of the en-
larged prostate. The PSA level measured 6 months postopera-
tively represented a considerable reduction, which indirectly 
indicated urinary symptom improvement.
  Pathologic examination was performed in all cases and re-
vealed malignancy in 17 patients (5%), including 1 patient with 
invasive TCC. The remaining patients were diagnosed with 
prostate adenocarcinoma, which was managed appropriately. 
This finding is comparable with reports of TURP and open 
prostatectomy [19,20]. The possibility of histological examina-
tion is a merit of HoLEP compared with ablative modalities 
such as holmium ablation of prostate or photoselective vapor-
ization. In addition, the natural history of incidentally detected 
prostate cancer will be addressed in another study. 
  There are limitations to our study. First, this study was a ret-
rospective cross-sectional review of data, which limits accurate 
comparison between different subsets of patients. Second, the 
patient data were limited to a relatively short follow-up period. 
Several authors reported 3 years follow-up results with sizable 
population [5]. Furthermore, a significant number of patients 
were lost to follow-up. This may be due to the fact that once pa-
tients experienced symptom improvement; they became un-
willing to visit the clinic because their conditions were not con-
sidered life threatening. 
  In conclusion, our intermediate postoperative follow-up data 
show that HoLEP is an effective and relatively safe surgical pro-
cedure for BPH. Further follow-up is needed to prove the long-
term durability of HoLEP. 34    www.einj.org
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